Large cap equipment rental stock United Rentals, Inc (NYSE: URI) reportedQ3 2017 earnings after the market closed on Wednesday with results beating Wall Street expectations. Total revenue was $1.766 billion and rental revenue was $1.536 billion versus $1.508 billion and $1.322 billion, respectively whilenet incomewas $199 million versus $187 million. Subsequent to the third quarter,United Rentals completed its previously announced acquisition of Neff Corporation for approximately $1.3 billion with theacquisition augmenting the Companys earthmoving capabilities and efficiencies of scale in key market areas -particularly fast-growing southern geographies. The CEO commented:
“Were very pleased with the gains we reported for the third quarter. These includesignificantly higher volume and time utilization, margin growth, and strong cash flow. Importantly, we delivered positive rental rates both sequentially and year-over-year for every month in the quarter.Our U.S. end markets are driving robust demand for our fleet, and Canada is continuing torebound. Giventhese many positive dynamics, andthe extended hurricane recoveries, weve raised our 2017 gross capex plan by up to $200 million to best serve the current and anticipated needs of our customers.”
stock market history: Newell Rubbermaid Inc.(NWL)
- [By Ben Levisohn]
Last week, Tiffany (TIF) CFO Ralph Nicolettileft the luxury retailer for Newell Brands (NWL). Wells Fargo’s Ike Boruchow and team argued that Nicoletti’s departure is “an untimely distraction” for a stock that can’t afford one:
- [By WWW.THESTREET.COM]
Cramer and the AAP team are looking at the rally in Newell Brands (NWL) and offering a technical point of view to pair with their fundamental long-term analysis of the company. Find out what they are telling their investment club members; get a free trial subscription to Action Alerts PLUS.
- [By Chris Lange]
The S&P 500 stock posting the largest daily percentage loss ahead of the close Wednesday was Newell Brands Inc. (NYSE: NWL) which traded downover 3% at $47.10. The stocks 52-week range is $43.43 to $55.08. Volume was nearly 17 million versus the daily average of 3.3 million shares.
stock market history: Adeptus Health Inc.(ADPT)
- [By Lisa Levin]
Shares of Adeptus Health Inc (NYSE: ADPT) were down around 30 percent to $1.30. Medical Properties Trust disclosed that it has agreed in principle with Deerfield Management to restructuring in bankruptcy to Adeptus Health.
- [By Lisa Levin]
Adeptus Health Inc (NASDAQ: ADPT) shares dropped 66 percent to $9.09 after the company posted downbeat quarterly results and lowered its FY16 EBITDA outlook.
stock market history: Core Laboratories N.V.(CLB)
- [By Craig Jones]
Core Laboratories N.V. (NYSE: CLB) performed poorly and it is in the oil business. Cramer wouldn’t buy it, because he doesn’t want to recommend a stock in the oil and gas business.
- [By Matthew DiLallo]
Core Laboratories (NYSE:CLB) literally has its ear to the ground when it comes to deciphering what’s going on in the oil market. The company studies oil reservoirs, which tell it what’s happening with production, giving it a deep level of understanding on the supply side of the market. Core Labs takes what the reservoirs are saying, compares this with other data, and then blends it into an informed macro view of the oil market, which CEO David Demshur shared on the company’s recent quarterly earnings conference call. Here are five things he says the reservoirs are telling us about what’s really going on in the oil market.
- [By Lisa Levin] Gainers Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) shares rose 18.4 percent to $68.65 in pre-market trading as the company reported upbeat results for its first quarter. Jack in the Box Inc. (NASDAQ: JACK) shares rose 9.5 percent to $111.60 in the pre-market trading session after the company posted better-than-expected earnings for its second quarter. The company also disclosed that it has retained Morgan Stanley to evaluate potential alternatives for Qdoba. Coherus Biosciences Inc (NASDAQ: CHRS) rose 9.8 percent to $24.20 in pre-market trading. Coherus BioSciences disclosed that it prevailed in ‘135 IPR decision. Qiwi PLC (NASDAQ: QIWI) rose 8.1 percent to $21.49 in pre-market trading after reporting strong quarterly results. Korea Electric Power Corporation (ADR) (NYSE: KEP) shares rose 7.9 percent to $20.00 in pre-market trading after dropping 4.33 percent on Tuesday Target Corporation (NYSE: TGT) shares rose 7.5 percent to $58.60 in pre-market trading after the company reported stronger-than-expected results for its first quarter. AngloGold Ashanti Limited (ADR) (NYSE: AU) rose 4.3 percent to $11.71 in pre-market trading after falling 0.09 percent on Tuesday. Colgate-Palmolive Company (NYSE: CL) rose 4.1 percent to $74.53 in pre-market trading after the NY Post reported that the company might be up for sale for $100 per share. Harmony Gold Mining Co. (ADR) (NYSE: HMY) rose 4 percent to $2.35 in pre-market trading after declining 1.74 percent on Tuesday. Core Laboratories N.V. (NYSE: CLB) rose 3.6 percent to $109.00 in pre-market trading after gaining 0.39 percent on Tuesday. Clovis Oncology Inc (NASDAQ: CLVS) rose 3.2 percent to $51.15 in pre-market trading. JP Morgan upgraded Clovis Oncology from Neutral to Overweight.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
stock market history: Paradise, Inc. (PARF)
- [By SEEKINGALPHA.COM]
Paradise Inc. (OTCPK:PARF)
This company is focused on producing candied fruit, which is the basic ingredient of fruitcakes a dessert popular during Thanksgiving and Christmas in the US. They also produce their own plastic containers for these. While this product might not be wildly popular or its demand increasing, the company has a commanding portion of the market share (as mentioned by the management) and its sales have been stable and the company is able to be profitable.
stock market history: Evoke Pharma, Inc.(EVOK)
- [By Cameron Saucier]
Evoke (Nasdaq: EVOK) is a pharmaceutical company that develops drug candidates intended to treat gastrointestinal diseases. EVOK rose 73% last month after it announced positive guidance from the FDA for Gimoti, a patented nasal delivery drug that is intended to treat gastroparesis in adult women. The positive results were from a second pre-NDA (New Drug Application) meeting Evoke had with the FDA. EVOK is currently trading at $2.67 per share and is down 9.83% as of Jan. 9 YOY.
- [By Lisa Levin]
Losers DBV Technologies SA – ADR (NASDAQ: DBVT) shares tumbled 50.6 percent to $23.73 after the company disclosed that its peanut allergy trial failed to meet primary endpoint. Connecture Inc (NASDAQ: CNXR) shares declined 40.8 percent to $0.290. Connecture reported that it will voluntarily delist from the NASDAQ for OTCQX Market. Walter Investment Management Corp (NYSE: WAC) slipped 19.2 percent to $0.410. On Friday, Walter Investment Management disclosed that it has reached an agreement with term lenders and senior noteholders on financial restructuring. Eldorado Gold Corp (USA) (NYSE: EGO) shares dropped 15.9 percent to $1.83. Eldorado Gold lowered its production guidance for its Kisladag operation. Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) shares fell 15.4 percent to $1.04. Future Fintech Group Inc (NASDAQ: FTFT) dropped 13.6 percent to $1.53. Future FinTech reported filing of proxy statement, including proposal for corporate restructuring. Concordia International Corp (NASDAQ: CXRX) shares fell 12.3 percent to $0.500 after dipping 38.71 percent on Friday. Aemetis Inc (NASDAQ: AMTX) shares declined 11.3 percent to $0.550 OncoSec Medical Inc (NASDAQ: ONCS) dipped 10.5 percent to $1.12. OncoSec reported a $7.1 million registered direct at-the-market offering at a price of $1.34375 per share. Evoke Pharma Inc (NASDAQ: EVOK) shares fell 10.35 percent to $3.08 after the company disclosed 'positive' topline results from comparative exposure pharmacokinetic study for Gimoti. Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) shares dropped 9.4 percent to $11.60 as the company disclosed Phase 2 interim 24-week data with pegylated interferon lambda in Hepatitis Delta Virus infection at the American Association for the Study of Liver Diseases Meeting. Viking Therapeutics Inc (NASDAQ: VKTX) shares slipped 6.6 percent to $2.80. Viking Therapeutics presented results from proof-of-concept study of VK0214 in in vivo
stock market history: KLA-Tencor Corporation(KLAC)
- [By Jim Cramer]
The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Semiconductors & Semiconductor Equipment industry. The net income increased by 45.2% when compared to the same quarter one year prior, rising from $72.23 million to $104.90 million.
- [By Jim Cramer]
The company’s current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Semiconductors & Semiconductor Equipment industry and the overall market, KLA-TENCOR CORP’s return on equity significantly exceeds that of both the industry average and the S&P 500.
- [By Jim Cramer]
After a year of stock price fluctuations, the net result is that KLAC’s price has not changed very much. Although its weak earnings growth may have played a role in this flat result, don’t lose sight of the fact that the performance of the overall market, as measured by the S&P 500 Index, was essentially similar. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
- [By Laurie Kulikowski]
We rate KLA-TENCOR CORP as a Hold with a ratings score of C. The primary factors that have impacted our rating are mixed – some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company’s strengths can be seen in multiple areas, such as its increase in net income, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet.